Amgen results beat estimates, lung cancer trial planned

Amgen results beat estimates, lung cancer trial planned

Source: 
Yahoo/Reuters
snippet: 

Amgen Inc <AMGN.O> on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped its results exceed Wall Street forecasts.